Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Infinity Pharmaceuticals and MedImmune have initiated a Phase Ib clinical trial of IPI-504 in combination with Taxotere(r) in patients with advanced solid tumors.
Subscribe to our email newsletter
The goal of this open-label, dose-escalation study is to establish the safety, maximum tolerated dose (MTD) and optimal schedule of administration for IPI-504 in combination with Taxotere. Initially, patients will receive 75mg/m2 of Taxotere followed by 300mg/m2 of IPI-504 on day one of each 21-day cycle. Once an MTD is reached, the trial will expand to enroll up to 20 additional patients. Additional schedules, including once-weekly dosing of IPI-504 and Taxotere, may also be explored as the trial progresses.
IPI-504, the companies’s lead heat shock protein 90 (Hsp90) inhibitor, is currently in clinical development for a number of solid tumor cancers. Enrollment for this new study has commenced at Memorial Sloan-Kettering Cancer Center in New York, with additional sites expected to be added as the study progresses.
David Grayzel, vice president, clinical development and medical affairs at Infinity, said: “This trial marks the first exploration of IPI-504 in combination with chemotherapy.”